MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-14-2022
Akouos EPS Ratio 2011-2026 | AKUS
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Akouos
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.52 | -2.77 | -42.5 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.52 | -42.5 | -15.9 |
Quarterly EPS Ratio Akouos
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -0.54 | -0.58 | -0.78 | - | -0.67 | -0.66 | -0.47 | - | -0.85 | -11.1 | -14.7 | - | -13.2 | -3.42 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -0.47 | -14.7 | -4.28 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M |  Germany |
 |
BioNTech SE
BNTX
|
42.2 | $ 97.57 | 2.17 % | $ 27.2 B | Germany |
 |
Aligos Therapeutics
ALGS
|
-2.45 | $ 8.49 | 6.25 % | $ 83.9 M |  USA |
 |
Alterity Therapeutics Limited
ATHE
|
-0.53 | $ 3.63 | -2.42 % | $ 8.73 B |  Australia |
 |
I-Mab
IMAB
|
-7.66 | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
-2.85 | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
-3.25 | - | - | $ 10.1 M | USA |
 |
Genfit SA
GNFT
|
1.51 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-0.26 | - | -13.47 % | $ 169 M | France |
 |
Applied Therapeutics
APLT
|
-1.42 | - | - | $ 8.42 M | USA |
 |
Midatech Pharma plc
MTP
|
-31 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Esperion Therapeutics
ESPR
|
-0.11 | $ 2.15 | -0.69 % | $ 447 M | USA |
 |
Evogene Ltd.
EVGN
|
-0.83 | $ 0.83 | 2.5 % | $ 27.9 M |  Israel |
 |
Amphastar Pharmaceuticals
AMPH
|
2.1 | $ 20.87 | 2.45 % | $ 976 M | USA |
 |
Genmab A/S
GMAB
|
34.4 | $ 28.23 | -0.07 % | $ 18 B |  Danmark |
 |
Grifols, S.A.
GRFS
|
0.28 | $ 8.24 | 0.3 % | $ 6.83 B |  Spain |
 |
GT Biopharma
GTBP
|
-6.68 | $ 0.37 | -0.92 % | $ 2.04 M | USA |
 |
Acorda Therapeutics
ACOR
|
-204 | - | -24.86 % | $ 820 K | USA |
 |
Halozyme Therapeutics
HALO
|
2.64 | $ 66.86 | -1.42 % | $ 8.01 B | USA |
 |
Adverum Biotechnologies
ADVM
|
-6.62 | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
-7.99 | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-0.07 | - | 5.93 % | $ 314 M |  Canada |
 |
Harmony Biosciences Holdings
HRMY
|
2.76 | $ 28.5 | -1.35 % | $ 1.64 B | USA |
 |
AgeX Therapeutics
AGE
|
-1.91 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-24.9 | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
-0.02 | $ 1.43 | 2.14 % | $ 368 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | USA |
 |
Allakos
ALLK
|
-2.14 | - | - | $ 28.6 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-5.97 | $ 2.91 | -0.26 % | $ 4.79 M | Israel |
 |
Aptinyx
APTX
|
-0.96 | - | -39.0 % | $ 4.57 M | USA |
 |
Aquestive Therapeutics
AQST
|
-0.78 | $ 4.18 | 2.45 % | $ 447 M | USA |
 |
Aravive
ARAV
|
-2.1 | - | -13.39 % | $ 1.45 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-0.13 | $ 23.96 | -1.03 % | $ 3.05 B | USA |
 |
AIkido Pharma
AIKI
|
-1.57 | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
-3.9 | $ 32.21 | -0.09 % | $ 2.14 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
-1.08 | $ 1.49 | -0.34 % | $ 397 M | Britain |
|
Immatics N.V.
IMTX
|
-4.77 | $ 10.59 | 1.53 % | $ 666 M | Germany |
 |
Aptose Biosciences
APTO
|
-10.4 | - | -45.71 % | $ 1.2 M | Canada |
 |
Incyte Corporation
INCY
|
6.59 | $ 94.65 | -1.48 % | $ 18.5 B | USA |
 |
Cidara Therapeutics
CDTX
|
-26.8 | - | - | $ 1.41 B | USA |
 |
Innate Pharma S.A.
IPHA
|
-0.66 | $ 1.48 | 4.61 % | $ 235 M | France |
 |
AVROBIO
AVRO
|
0.27 | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.46 | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-2.16 | $ 2.57 | 0.78 % | $ 16.1 M | USA |
 |
AstraZeneca PLC
AZN
|
0.08 | - | - | $ 96.9 B | Britain |
 |
Inventiva S.A.
IVA
|
-1.27 | $ 5.15 | -2.09 % | $ 138 M | France |
 |
Akero Therapeutics
AKRO
|
-3.75 | - | - | $ 3.67 B | USA |